Hepatitis B virus reactivation and prophylaxis

doi:10.3877/cma.j.issn.1674-1358.2017.01.002

Abstract

Abstract:

It is estimated that two billion people have had hepatitis B virus (HBV) infection worldwide. Any immunocompromised status will change the state of HBV infection and lead to HBV reactivation. The consequences of reactivation could be asymptomatic, fulminant hepatitis, hepatic failure and even death. The reactivation rate of HBV ranges from 24% to 88% with different risk factors, and the mortality rate is higher than 10%. The risk factors include the use of biological agents and glucocorticoids, high level of viral load at baseline, and positive HBV surface antigen, etc. All candidates for chemotherapy and immunosuppressive therapy should be screened for HBV infection, and receive risk classification and then prevention and treatment, which is significant for preventing the hazard that caused by HBV reactivation.

Key words: Hepatitis B virus, Reactivation, Prophylaxis

Mengyang Zhang, Shuo Zhang, Baotong Zhou, Xiaoqing Liu. Hepatitis B virus reactivation and prophylaxis[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(01): 4-9.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.01.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I01/4

Figures/Tables 2

References 49

1	Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine,2012,30(12):2212-2219.
2	Hoofnagle JH. Reactivation of hepatitis B[J]. Hepatology,2009,49(Suppl 5):S156-S165.
3	Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J]. Ann Intern Med,2008,148(7):519-528.
4	Hwang JP, Lok ASF. Management of patients with hepatitis B who require immunosuppressive therapy[J]. Nature Reviews Gastroenterology & Hepatology Nat Rev Gastroenterol Hepatol,2013,11(4):209-219.
5	Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization[J]. Hepatology,2006,43(2):233-240.
6	Saab S, Dong MH, Joseph TA, et al. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model[J]. Hepatology,2007,46(4):1049-1056.
7	Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy[J]. Gut,2010,59(10):1340-1346.
8	Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases[J]. Medicine (Baltimore),2011,90(6):359-371.
9	Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J]. Gastroenterology,2015,148(1):215-219, e16-e17.
10	Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study[J]. J Clin Oncol,2014,32(33):3736-3743.
11	Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group[J]. Eur J Cancer,2013,49(16):3486-3496.
12	Dong HJ, Ni LN, Sheng GF, et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis[J]. J Clin Virol,2013,57(3):209-214.
13	Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol,2009,27(4):605-611.
14	Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting[J]. Br J Dermatol,2013,168(3):609-616.
15	Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF-alpha agents: a retrospective analysis of 49 cases[J]. Clin Rheumatol,2012,31(6):931-936.
16	Kim PS, Ho GY, Prete PE, et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B[J]. Arthritis Care Res (Hoboken),2012,64(8):1265-1268.
17	Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy[J]. Clin Exp Rheumatol,2013,31(1):118-121.
18	Chyuan IT, Tsai HF, Tzeng HT, et al. Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model[J]. Cell Mol Immunol,2015,12(3):317-325.
19	Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection[J]. Nat Rev Rheumatol,2010,6(3):165-174.
20	Okuyama-Dobashi K, Kasai H, Tanaka T, et al. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide[J]. Sci Rep,2015,5:17047.
21	Chou CK, Wang LH, Lin HM, et al. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells[J]. Hepatology,1992,16(1):13-18.
22	Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element[J]. Proc Natl Acad Sci USA,1986,83(6):1627-1631.
23	Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer[J]. Virology,1988,167(2):630-633.
24	Cheng A. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J]. Hepatology,2003,37(6):1320-1328.
25	中华医学会血液学分会，中国抗癌协会淋巴瘤专业委员会，中华医学会肝病学分会. 中国淋巴瘤合并HBV感染患者管理专家共识[J]. 中华血液学杂志,2013,34(11):988-993.
26	Hsu CH, Hsu HC, Chen HL, et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy[J]. Anticancer Res,2004,24(5A):3035-3040.
27	Liang RH, Lok AS, Lai CL, et al. Hepatitis B infection in patients with lymphomas[J]. Hematol Oncol,1990,8(5):261-270.
28	Hsiao LT, Chiou TJ, Gau JP, et al. Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab-treated non-hodgkin lymphoma patients: a large cohort retrospective study[J]. Medicine (Baltimore),2015,94(32):e1321.
29	Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy[J]. Br J Cancer,2004,90(7):1306-1311.
30	Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study[J]. J Med Virol,2003,70(4):553-561.
31	Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy[J]. Br J Cancer,2011,104(4):559-563.
32	Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients[J]. Hepatology,2002,36(5):1246-1252.
33	Chen GD, Gu JL, Qiu J, et al. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers[J]. Transpl Infect Dis,2013,15(3):300-305.
34	Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy[J]. Gastroenterology,2003,125(6):1742-1749.
35	Hammond SP, Borchelt AM, Ukomadu C, et al. Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant 2009,15(9):1049-1059.
36	Visram A, Chan KK, Mcgee P, et al. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening[J]. PLoS One,2015,10(4):e120749.
37	Hwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy[J]. J Oncol Pract,2012,8(4):e32-e39.
38	Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2006,24(7):1003-1016.
39	Paul S, Saxena A, Terrin N, et al. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis[J]. Ann Intern Med,2016,164(1):30-40.
40	EASL Clinical Practice Guidelines: Management of chronic hepatitis B[J]. J Hepatol,2009,50(2):227-242.
41	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015,31(12):1941-1960.
42	Lok AS, Mcmahon BJ. Chronic hepatitis B: update 2009[J]. Hepatology,2009,50(3):661-662.
43	Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int,2016,10(1):1-98.
44	Chen WC, Cheng JS, Chiang PH, et al. A Comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy[J]. PLoS One,2015,10(6):e131545.
45	Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy[J]. Nat Rev Gastroenterol Hepatol,2014,11(4):209-219.
46	Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy[J]. Hepatology,2009,49(5):1503-1514.
47	Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients[J]. Clin Infect Dis,2010,51(5):496-505.
48	Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial[J]. JAMA,2014,312(23):2521-2530.
49	Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute Technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J]. Gastroenterology,2015,148(1):221-244.

影响因素	预测HBV再激活率	HBsAg	HBcAb	糖皮质激素	其他药物
高危因素	> 10%	+	+	/	B细胞单克隆抗^a
		-	+	/	B细胞单克隆抗体
		+	+	/	蒽环类衍生物^b
		+	+	每日中等剂量^c或大剂量^d疗程≥ 4周	/
中危因素	1%～10%	+	+	/	抗TNFα^e，细胞因子单克隆抗体^f，酪氨酸激酶抑制剂^g
		-	+	/	抗TNFα，细胞因子单克隆抗体，酪氨酸激酶抑制剂，蒽环类衍生物
		+	+	每日小剂量^h疗程≥ 4周	/
		-	+	每日中等剂量或大剂量疗程≥ 4周	/
低危因素	< 1%	+	+	/	硫唑嘌呤，甲氨蝶呤，关节内糖皮质激素治疗
		-	+	/	硫唑嘌呤，甲氨蝶呤
		+	+	任意剂量疗程≤ 1周	/
		-	+	任意剂量疗程≤ 1周	/
		+	+	小剂量疗程≥ 4周	/

影响因素	预测HBV再激活率	HBsAg	HBcAb	糖皮质激素	其他药物
高危因素	> 10%	+	+	/	B细胞单克隆抗^a
		-	+	/	B细胞单克隆抗体
		+	+	/	蒽环类衍生物^b
		+	+	每日中等剂量^c或大剂量^d疗程≥ 4周	/
中危因素	1%～10%	+	+	/	抗TNFα^e，细胞因子单克隆抗体^f，酪氨酸激酶抑制剂^g
		-	+	/	抗TNFα，细胞因子单克隆抗体，酪氨酸激酶抑制剂，蒽环类衍生物
		+	+	每日小剂量^h疗程≥ 4周	/
		-	+	每日中等剂量或大剂量疗程≥ 4周	/
低危因素	< 1%	+	+	/	硫唑嘌呤，甲氨蝶呤，关节内糖皮质激素治疗
		-	+	/	硫唑嘌呤，甲氨蝶呤
		+	+	任意剂量疗程≤ 1周	/
		-	+	任意剂量疗程≤ 1周	/
		+	+	小剂量疗程≥ 4周	/

指南	筛查人群	筛查项目	预防用药疗程	药物选择	疫苗
中国慢乙型肝炎指南2015版^[41]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb、HBV DNA	治疗前1周至停止治疗后6个月	恩替卡韦或替诺福韦酯	/
AASLD2009版^[42]	高危人群	HBsAg、HBcAb	HBV DNA<2 000 U/ml，停止治疗后6个月；HBV DNA >2 000 U/ml，同慢性乙型肝炎患者的治疗终点	预期治疗持续时间较短（≤ 12个月）且，血清HBV DNA低于检测下限，拉米夫定或替比夫定；预期治疗持续时间较长，则优选恩替卡韦或替诺福韦酯	/
EASL2012版^[40]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	预期治疗持续时间较短，HBV DNA< 2 000 U/ml，拉米夫定；预期治疗持续时间较长，HBV DNA> 2 000 U/ml，选择恩替卡韦和替诺福韦酯	血清学阴性时
AGA2015版^[9]	中高危人群	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后6个月；B细胞单克隆抗体最少12个月	建议采用更不易产生耐药性的药物	/
APASL2015版^[43]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	/	HBsAb阴性时

指南	筛查人群	筛查项目	预防用药疗程	药物选择	疫苗
中国慢乙型肝炎指南2015版^[41]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb、HBV DNA	治疗前1周至停止治疗后6个月	恩替卡韦或替诺福韦酯	/
AASLD2009版^[42]	高危人群	HBsAg、HBcAb	HBV DNA<2 000 U/ml，停止治疗后6个月；HBV DNA >2 000 U/ml，同慢性乙型肝炎患者的治疗终点	预期治疗持续时间较短（≤ 12个月）且，血清HBV DNA低于检测下限，拉米夫定或替比夫定；预期治疗持续时间较长，则优选恩替卡韦或替诺福韦酯	/
EASL2012版^[40]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	预期治疗持续时间较短，HBV DNA< 2 000 U/ml，拉米夫定；预期治疗持续时间较长，HBV DNA> 2 000 U/ml，选择恩替卡韦和替诺福韦酯	血清学阴性时
AGA2015版^[9]	中高危人群	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后6个月；B细胞单克隆抗体最少12个月	建议采用更不易产生耐药性的药物	/
APASL2015版^[43]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	/	HBsAb阴性时

[1]	Xiaofang Zhang, Ying Zhang, Xianjin Liu, Hong Xue. Comparision of three common index systems in evaluating short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2022, 15(05): 353-359.
[2]	Xiaoman Zhang, Xiaoqiu Ma, Zhengju Xu, Chunyu Zhang, Caiting He. Effect of drug-resistant mutations in reverse transcriptase region of hepatitis B virus on the level of serum hepatitis B surface antigen [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 324-332.
[3]	Yingying Wang, Ping Xie. Risk factors of liver injury in patients with hepatitis B virus infection and pulmonary tuberculosis and predictive model construction [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(04): 267-273.
[4]	Qianying Zhuang, Li Li, Wenjing Wang, Xiaodi Kang, Suping Wang. Effect of hepatitis B virus on pregnancy outcome of patients undergoing in vitro fertilization and embryo transfer [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(06): 426-430.
[5]	Chuanju Li, Linyue Liu, Mei Wang, Xin Li, Xianghui Han, Haiyong Jia. Progress on models of hepatitis B virus infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(06): 361-365.
[6]	Junwen Wang, Yuan Tian, Zihao Fan, Ling Xu, Yao Gao, Yaling Cao, Zhenzhen Pan, Xiangying Zhang, Yan Song, Feng Ren. Establishment of a method for the detection of hepatitis B virus covalently closed circular DNA based on clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins technology [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(05): 320-327.
[7]	Fang Xie, Xi Xiong, Chuanxia Yao, Haonan Sun, Ping Li, Maorong Wang. Clinical efficacy and influencing factors of pegylated interferon alfa-2b and nucleos(t)ide analogue in chronic hepatitis B patients with low level of hepatitis B virus surface antigen [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(04): 247-253.
[8]	Xiyan Zheng, Zheng Zhou, Fangping He, Zhiqun Lin, Fei Du, Qin Xie, Shaoping Wang, Xianjie Shi. Risk factors for the prognosis of metabolic syndrome and hepatitis B virus related hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 104-109.
[9]	Xuexue Lei, Ying Yu, Hongyan Li. Clinical research of multimodal prehabilitation optimization program in patients with hepatitis B virus-related liver cirrhosis awaiting liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 158-163.
[10]	Committee of Health Management for Organ Transplant Recipient, China Organ Transplantation Development Foundation. Expert guidance on prophylaxis strategies and health management of organ transplant recipients infected with COVID-19 in China (first edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 1-12.
[11]	Shudian Chen, Yun Liang, Yuan Liao, Yang Wang. Prognostic value of complement C3 in patients with HBV-related acute-on-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 562-566.
[12]	Yang Li, Yabo Shi, Jianhua Tu. Risk factors and prophylaxis for pancreatic fistula after pancreaticoduodenectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(03): 352-355.
[13]	Jingdong Li, Xujian Huang. Causes and prophylaxis for iatrogenic bile duct injury in laparoscopic hepatectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(04): 335-337.
[14]	Chong Chen, Ranran You, Min Wang, Haojie Zhou. Blood safety analysis of single-HBsAg-reagent(+)/NAT(-) blood donors [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(02): 95-98,104.
[15]	Huiping Wei, Yingming Guo, Guirong Liu, Zongyou Wu, Qiuqing Weng. Application value of superoxide dismutase test in hepatitis B virus related liver disease [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(01): 21-26.

Please choose a citation manager

Content to export